An Investigator-Initiated Phase I Study of Selinexor (KPT-330), Ixazomib, and Low Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Latest Information Update: 30 Nov 2020
At a glance
- Drugs Selinexor (Primary) ; Dexamethasone; Ixazomib
- Indications Multiple myeloma
- Focus Adverse reactions
- 23 Nov 2020 Status changed from active, no longer recruiting to completed.
- 08 Oct 2020 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
- 08 Oct 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2021.